{"corpus_id":6241664,"paper_sha":"42bcd2cf9ea82b17255edb1ef21a3d5c8891f6f4","doi":"10.1111/cas.12986","arxiv_id":null,"pmid":27297395,"pmcid":"5021038","mag_id":2514374718,"dblp_id":null,"acl_id":null,"title":"Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer","year":2016,"publication_date":"2016-08-25","venue":"Cancer Science","journal":{"name":"Cancer Science","pages":"1193 - 1197","volume":"107"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Review"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":81,"citation_count":167,"influential_citation_count":8,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antibodies, Monoclonal","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000911"},{"d":"Antigens, CD","mj":false,"qs":[{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D015703"},{"d":"B7-H1 Antigen","mj":false,"qs":[{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D060890"},{"d":"CTLA-4 Antigen","mj":false,"qs":[{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D060908"},{"d":"Disease Susceptibility","mj":false,"ui":"D004198"},{"d":"Drug Discovery","mj":false,"ui":"D055808"},{"d":"Gene Expression","mj":false,"ui":"D015870"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Immunomodulation","mj":true,"qs":[{"q":"genetics","mj":false,"ui":"Q000235"}],"ui":"D056747"},{"d":"Molecular Targeted Therapy","mj":false,"ui":"D058990"},{"d":"Neoplasms","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"immunology","mj":true,"ui":"Q000276"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D009369"},{"d":"Programmed Cell Death 1 Receptor","mj":false,"qs":[{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D061026"},{"d":"Signal Transduction","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D015398"},{"d":"T-Lymphocyte Subsets","mj":false,"qs":[{"q":"immunology","mj":false,"ui":"Q000276"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D016176"},{"d":"Lymphocyte Activation Gene 3 Protein","mj":false,"ui":"D000093322"}],"chemicals":[{"n":"Antibodies, Monoclonal","ui":"D000911","reg":"0"},{"n":"Antigens, CD","ui":"D015703","reg":"0"},{"n":"B7-H1 Antigen","ui":"D060890","reg":"0"},{"n":"CTLA-4 Antigen","ui":"D060908","reg":"0"},{"n":"Programmed Cell Death 1 Receptor","ui":"D061026","reg":"0"},{"n":"Lymphocyte Activation Gene 3 Protein","ui":"D000093322","reg":"0"},{"n":"Lag3 protein, human","ui":"C000720326","reg":"0"},{"n":"soluble LAG-3 protein, human","ui":"C000720328","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12986","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/42bcd2cf9ea82b17255edb1ef21a3d5c8891f6f4","s2_open_access_license":"CCBYNCND","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen‐4 (CTLA‐4), programmed cell death ligand‐1 (PD‐L1) and programmed cell death‐1 (PD‐1). Immunotherapy targeting the PD‐1/PD‐L1 checkpoints has shown promising efficacy in non‐small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the simultaneous inhibition of other checkpoints could improve outcomes. Lymphocyte‐activation gene‐3 (LAG‐3) is another vital checkpoint that may have a synergistic interaction with PD‐1/PD‐L1. Here we review the LAG‐3 function in cancer, clinical trials with agents targeting LAG‐3 and the correlation of LAG‐3 with other checkpoints.","claims":[{"public_id":"cl_7fd6f9dd86c641257c02b35bdc9bc826","status":"active","text":"Clinical trials of agents targeting LAG-3 are reviewed alongside its function in cancer and its correlation with other checkpoints.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7fd6f9dd86c641257c02b35bdc9bc826"},{"public_id":"cl_79c7e5f2941fb1c50b53cc661aef3fb6","status":"active","text":"LAG-3 is a vital immune checkpoint that may act synergistically with PD-1/PD-L1 in cancer.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_79c7e5f2941fb1c50b53cc661aef3fb6"}],"concepts":[{"public_id":"co_282c6834effaa15ffb6f631c29856020","status":"active","name":"agents targeting LAG-3","description":"Therapeutic agents designed to inhibit or modulate LAG-3 activity.","types":["therapy","drug class"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_282c6834effaa15ffb6f631c29856020"},{"public_id":"co_2e96b6aff5a01b2cee218fb6649bcbbc","status":"active","name":"synergistic interaction","description":"A cooperative interaction in which combined targeting may improve treatment effect.","types":["interaction"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2e96b6aff5a01b2cee218fb6649bcbbc"},{"public_id":"co_53a5174f319e12b47e996e90d7b9f180","status":"active","name":"PD-1/PD-L1","description":"The programmed cell death-1 and programmed cell death ligand-1 checkpoint axis targeted by immunotherapy.","types":["immune checkpoint"],"aliases":["PD-1","PD-L1","programmed cell death-1","programmed cell death ligand-1"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_53a5174f319e12b47e996e90d7b9f180"},{"public_id":"co_7a890eaf2237b6b16e975c5c3041384c","status":"active","name":"lung cancer","description":"A cancer of the lung discussed as the clinical setting for immunotherapy use.","types":["disease"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7a890eaf2237b6b16e975c5c3041384c"},{"public_id":"co_a11f2be5c6f5b23f6f0902d4b01bd91a","status":"active","name":"LAG-3","description":"Lymphocyte-activation gene-3, an immune checkpoint molecule implicated in antitumor immune regulation.","types":["immune checkpoint"],"aliases":["lymphocyte-activation gene-3"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a11f2be5c6f5b23f6f0902d4b01bd91a"},{"public_id":"co_a7e8ae3498ecc09f81b3397a9b17c4df","status":"active","name":"non-small cell lung cancer","description":"A major subtype of lung cancer used here as the disease context for PD-1/PD-L1 immunotherapy.","types":["disease"],"aliases":["NSCLC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a7e8ae3498ecc09f81b3397a9b17c4df"},{"public_id":"co_af94c501314ad00f24698a04b3b1e397","status":"active","name":"other checkpoints","description":"Additional immune checkpoint targets considered for combined inhibition with LAG-3.","types":["immune checkpoint"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_af94c501314ad00f24698a04b3b1e397"},{"public_id":"co_b1f00994f25ad099f7cf2873537cba85","status":"active","name":"cancer","description":"A group of malignant diseases involving uncontrolled cell growth, used here as the disease context for immune checkpoint targeting.","types":["disease"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b1f00994f25ad099f7cf2873537cba85"},{"public_id":"co_b9ecd43b34941e1a6e929c46d40213ae","status":"active","name":"clinical trials","description":"Human studies evaluating agents targeting LAG-3.","types":["study type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b9ecd43b34941e1a6e929c46d40213ae"},{"public_id":"co_bb9362b1cc3e50b405f3b41b297a3f01","status":"active","name":"immunotherapy","description":"Treatment that modulates the immune system to combat cancer.","types":["therapy"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bb9362b1cc3e50b405f3b41b297a3f01"},{"public_id":"co_e2a9e1cf45775fe62816ec737c87161f","status":"active","name":"CTLA-4","description":"Cytotoxic T lymphocyte antigen-4, another immune checkpoint mentioned for comparison in cancer immunotherapy.","types":["immune checkpoint"],"aliases":["cytotoxic T lymphocyte antigen-4"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e2a9e1cf45775fe62816ec737c87161f"}],"external_ids":{"DOI":"10.1111/cas.12986","ArXiv":null,"PubMed":27297395,"PubMedCentral":"5021038","MAG":2514374718,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12986","landing_url":"https://www.semanticscholar.org/paper/42bcd2cf9ea82b17255edb1ef21a3d5c8891f6f4","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":638387,"paper_uid":"ba5a9d10-47d0-4a82-a4d2-2c2e172ba49e","canonical_identity":{"paper_id":638387,"paper_uid":"ba5a9d10-47d0-4a82-a4d2-2c2e172ba49e","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/6241664"}